Track topics on Twitter Track topics that are important to you
BriaCell Therapeutics announces that the Phase I/IIa clinical study of Bria-IMT™ with Incyte Corporation’s immune checkpoint inhibitor, is ongoing.
The post BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic appeared first on Investing News Network.
Original Article: BriaCell Continues Clinical Operations Amidst COVID-19 PandemicNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...